Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Solid Tumor : High risk abdominal neuroblastoma
Neuroblastoma commonly develops in nerve cells outside of the brain. Neuroblastoma shows up as a lump or mass most frequently in the belly but also in the neck, chest, abdomen or pelvis. It often spreads to bone, lymph nodes, liver and bone marrow (the soft tissue in the center of bones where blood cells are made). In high risk neuroblastoma patients, tumor has either spread from where it started or is harder to treat because it has special characteristics making it behave more aggressively. The standard treatment for patients with high-risk abdominal neuroblastoma is a combination of chemotherapy (drugs), surgery, bone marrow transplant, radiation therapy and immunotherapy (treatment using antibodies to get rid of cancer in the body).
The purpose of this study is to learn what impact breathing has on the motion of the area where the tumor was/is and also the kidneys which are often situated right next to the original tumor site. One part of the study is to measure different types of motion with breathing by using an elastic band with a pressure sensor placed around the abdomen to estimate what is happening with each breath. The elastic band measures how much the wall of the abdomen moves with each breath, and this gives the study team a way to estimate how the diaphragm and other normal organs within the belly move. By looking at this motion, the study team will have a better ability to predict how things in the patient belly move, and they can do a better job of reducing harmful radiation dose to normal tissues like the kidneys, while increasing the amount of dose delivered to the areas that need it.
A retrospective review of patients treated with these methods yielded zero failures in 20 kids after almost 2 years of follow-up.
The standard of care radiation plan will still be delivered, but with this information the study team will be able to adjust their treatments to minimize the toxicities of radiation while possibly improving the ability to treat the area where the tumorwas/is. All of the technologies used to deliver this treatment are approved by the Food and Drug Administration for use in children with high-risk abdominal neuroblastoma.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Atmaram S. Pai Panandiker, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
Referring or consulting physicians only: firstname.lastname@example.org
For all other inquiries about St. Jude Children's Research Hospital studies: email@example.com
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.